Luca Patti

Luca Patti

Auto-generated profile, based on publicly available information

Luca Patti

Endocrinologia, Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università di Genova, Genova, Italia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2021 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
MAManuela Albertelli
Manuela Albertelli
ADAndrea Dotto
Andrea Dotto
FNFederica Nista
Federica Nista
AVAlessandro Veresani
Alessandro Veresani
LPLuca Patti
Luca Patti
DFDiego Ferone
Diego Ferone
Immunotherapy, so promising in many neoplasms, still does not have a precise role in the treatment of neuroendocrine neoplasms (NENs). In this article, we provide an overview on the current knowledge about immunotherapy with immune checkpoint inhibitors (ICIs) applied to NENs, evaluating future perspectives in this setting of tumors.Evidence so far available for ICIs in gastroenteropancreatic (GEP)-NENs is definitively not as robust as for other tumors such as Small Cell Lung Cancer or Merkel Cell Carcinoma. In fact, with regard to the well-differentiated forms of NENs (NETs), the results obtained nowadays have been disappointing. However, the near future, might reserve interesting results for ICIs in GEP-NEN from a total of nine different ICI drugs, used throughout 19 randomised controlled trials. Such numbers highlight the growing attention gathering around NENs and ICIs, in response to the need of stronger evidences supporting such therapy.For the future, the most important aspect will be to study strategies that can make NETs more susceptible to response to ICI and, thus, enhance the effectiveness of these treatments. Therefore, the combination of conventional therapy, target therapy and immunotherapy deserve attention and warrant to be explored. A sequential chemotherapy, possibly inducing an increase in tumor mutational burden and tested before immunotherapy, could be a hypothesis deserving more consideration. A radiation treatment that increases tumor-infiltrating lymphocytes, could be another approach to explore before ICIs in NENs. Equally essential will be the identification of biomarkers useful for selecting patients potentially responsive to this type of treatment.

29 March 2022 in L'Endocrinologo
Verified
Journal Article
Open access
PDF file
LPLuca Patti
Luca Patti
LMLaura Musso
Laura Musso
DFDiego Ferone
Diego Ferone
MAManuela Albertelli
Manuela Albertelli
Sommario Gli inibitori dei checkpoint immunitari (ICIs) causano frequentemente eventi avversi immuno-correlati di tipo endocrino. La tiroide, in particolare, è l’organo maggiormente interessato e l’ipotiroidismo risulta essere la disfunzione più comune durante la terapia con ICIs. È importante, quindi, effettuare un adeguato monitoraggio clinico e biochimico nei pazienti trattati con ICIs, in modo da ridurre le complicanze e ottenere una maggiore aderenza terapeutica al trattamento oncologico.